Why the study?
The short-term outcomes, prognosis, and cardiac safety of pegylated liposomal doxorubicin-based neoadjuvant chemotherapy compared to epirubicin-based therapy in breast cancer remained to be evaluated.
Does Pegylated Liposomal Doxorubicin-based neoadjuvant chemotherapy improve overall and disease-free survival compared to epirubicin-based therapy in patients with stage II-III breast cancer?
Population
304 patients diagnosed with stages II and III breast cancer
Comparison
PLD-based NAC vs epirubicin-based NAC
Key result
Pegylated liposomal doxorubicin-based neoadjuvant chemotherapy significantly reduced the risk of disease recurrence by 48% (HR 0.52) compared to epirubicin-based therapy in patients with stage II-III breast cancer.
Authors
Loading...
May support PLD preference in neoadjuvant breast cancer; hypothesis-generating pending randomized confirmation.
Cohort (n=304)
No
Does Pegylated Liposomal Doxorubicin-based neoadjuvant chemotherapy improve overall and disease-free survival compared to epirubicin-based therapy in patients with stage II-III breast cancer?
Hazard Ratio: 0.52 (95% CI 0.3–0.92)
Absolute Event Rate: 84.5% vs 72.9%
p-value: p=0.0227
PLD-based neoadjuvant chemotherapy significantly improves disease-free and overall survival compared to epirubicin in stage II-III breast cancer, without increasing cardiotoxicity.
Li et al. (2024) conducted a cohort in Stages II and III breast cancer (n=304). Pegylated Liposomal Doxorubicin (PLD) vs. Epirubicin was evaluated on 5-year Disease-Free Survival (DFS) (HR 0.52, 95% CI 0.30-0.92, p=0.0227). Pegylated liposomal doxorubicin-based neoadjuvant chemotherapy significantly reduced the risk of disease recurrence by 48% (HR 0.52) compared to epirubicin-based therapy in patients with stage II-III breast cancer.